在青少年患者中对铁性脱脂盐的回顾性单中心研究
Stephanie McMahon1, Rishi Gupta2, Erica Zak3
1Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Rochester Medical Center, Rochester, New York, USA.
Pediatric blood & cancer
|June 24, 2025
概括
静脉注射铁甲 (FDI) 有效治疗青少年缺铁性贫血 (IDA) 和缺铁 (ID). 这项现实研究显示耐受性良好,血红蛋白和费里水平显著改善.
科学领域:
- 儿科血液学 儿科血液学
- 药理学 药理学是指药理学的学科.
- 临床治疗学 临床治疗学
背景情况:
- 静脉注射 (IV) 铁配方对于管理青少年缺铁性贫血 (IDA) 和缺铁 (ID) 非常重要.
- 铁脱脂糖 (FDI) 是一种静脉铁配方,关于其在青少年群体中的使用,公布的数据有限.
- 了解不同静脉注射铁配方的疗效和安全性对于优化患者护理至关重要.
研究的目的:
- 评估青少年患者对IV铁性脱硫糖 (FDI) 的实际使用和临床反应.
- 评估IV FDI在这个特定年龄组的安全性,包括输液反应.
- 为了比较IV FDI在改善IDA和ID的青少年中的血红蛋白和费里丁水平的疗效.
主要方法:
- 在一个单一的三级医院接受静脉注射铁甲醇 (FDI) 的青少年患者的回顾性审查.
- 对36次输液总量进行分析,记录患者人口统计,诊断 (IDA或ID) 和治疗结果.
- 监测不良事件,特别是输液反应和过敏反应,并跟踪输液后血红蛋白和费里丁水平的变化.
主要成果:
- 在36次输液中观察到两个输液反应,没有过敏反应的情况,这表明了有利的安全性.
- 患有缺铁性贫血 (IDA) 的青少年平均血红蛋白增加3.0g/dL.
- 患有铁缺乏症 (ID) 的青少年平均铁素增加了224.7g/L,证明了治疗的有效性.
结论:
- 静脉注射铁甲醇 (FDI) 在治疗青少年缺铁性贫血 (IDA) 和缺铁 (ID) 方面表现出良好的耐受性和有效性.
- 在青少年中观察到的安全性和反应似乎与成年人群中报告的安全性和反应相似.
- 现实数据支持使用IV FDI作为青少年缺铁症的可行治疗选择.
相关概念视频
Glucose Transporters
15.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
15.2K
Bioavailability Study Design: Healthy Subjects Versus Patients
248
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
248
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Metabolism
410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Hyperosmolar Hyperglycemic State
20
Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...
20


